Anti-KOR-SA3544 (Human) mAb-FITC

WB - 10 ug/mL FCM - 20 uL

This monoclonal antibody (clone KOR-SA3544) was reactive with a surface antigen expressed on Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) without exception (26/26 cases). The recognized antigen is a nonspecific cross-reacting antigen (NCA)-50/90 (CD66c), one of the carcinoembryonic antigen (CEA)-related glycoproteins encoded by a member of the CEA gene family. The Philadelphia chromosome (Ph1) has been implicated as the causative factor in greater than 90% of chronic myelogenous leukemia (CML), in 25-30% of adult and 2-10% of childhood acute lymphoblastic leukemia (ALL) and in rare cases of acute myelogenous leukemia (AML). The presence of the Ph in leukemic cells of ALL patients usually indicates poor prognosis and high risk. Sequential monitoring of the Ph in ALL correlates with the activity of malignant clones and predicts impending clinical relapse, and therefore is useful in guiding clinical therapeutic decisions.

FITC

20 ug/mL in PBS/1% BSA/0.09% sodium azide

Human: 4680

KOCL-22 myeloid cell line derived from congenital leukemia

The reactivity of this antibody has been reported as follows. Common ALL a 5/38 (13.2%) Early B precursor ALL b 1 c /21 (4.8%) T - ALL 0/19 B - ALL 0/6 B - CLL/HCL 0/3 Multiple myeloma 0/2 ANLL 16/56 (28.6%) Ph1 - ALL 26/26 d (100%) CML blastic crisis 0/9 T - NHL 0/5 B - NHL 0/4 Hodgkin's disease 0/1 CLL, chronic lymphocytic leukemia HCL, hairy cell leukemia NHL, non - Hodgkin's lymphoma a C D10 + , CD19 + , HLA - DR + b CD10 - , CD19 + , HLA - DR + c One patient with 11q23 translocation. d Eighteen patients with m - bcr, eight patients with M - bcr

1 year

This antibody was purified from ascites fluid (clone KOR - SA3544) using protein A agarose. This hybr idoma was established by fusion of mouse myeloma cell 63.Ag8.653/NS1 with Balb/c mouse splenocyte immunized with a cell line (KOCL - 22 ) established from bone marrow blood of patient with congenital leukemia.

KOR-SA3544